Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 2,188,820 |
|
|||||
| News | - | ||||||
| Day High | 784.325 | Low High |
|||||
| Day Low | 766.12 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Eli Lilly and Co | LLY | NYSE | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 13.51 | 1.75% | 783.51 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 766.90 | 766.12 | 784.325 | 783.18 | 770.00 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 69,368 | 2,188,820 | US$ 780.57 | US$ 1,708,533,772 | - | 419.80 - 800.78 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:59:09 | 1 | US$ 783.795 | USD |
Eli Lilly (LLY) Options Flow Summary
Eli Lilly and Co Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 744.15B | 950.16M | - | 34.12B | 5.24B | 5.52 | 142.00 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Eli Lilly News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LLY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 763.05 | 787.66 | 750.53 | 771.83 | 2,164,883 | 20.46 | 2.68% |
| 1 Month | 729.74 | 795.4975 | 718.30 | 759.55 | 2,786,704 | 53.77 | 7.37% |
| 3 Months | 771.30 | 800.78 | 718.30 | 762.69 | 2,748,939 | 12.21 | 1.58% |
| 6 Months | 592.00 | 800.78 | 561.65 | 697.03 | 2,954,271 | 191.51 | 32.35% |
| 1 Year | 444.52 | 800.78 | 419.80 | 609.58 | 3,000,877 | 338.99 | 76.26% |
| 3 Years | 197.16 | 800.78 | 195.50 | 400.73 | 2,993,402 | 586.35 | 297.40% |
| 5 Years | 115.87 | 800.78 | 101.36 | 283.87 | 3,311,436 | 667.64 | 576.20% |
Eli Lilly Description
| Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. |
